Anzeige
Erschienen in:
06.02.2020 | Correction
Correction to: Outcomes of endoscopic treatment for malignant biliary obstruction in patients with surgically altered anatomy: analysis of risk factors for clinical failure
Erschienen in: Surgical Endoscopy | Ausgabe 1/2021
Einloggen, um Zugang zu erhaltenExcerpt
There are several places where the P-value and Odds ratio in Table 3 are incorrect: these are shown in the corrected Table 3.
Table 3
Risk factor for clinical failure via endoscopic treatment of MBO in patients with surgically altered anatomy
|
Clinical failure
|
Clinical success
|
Univariate analysis
|
Multivariate analysis
|
|||||
|---|---|---|---|---|---|---|---|---|
|
n = 14
|
n = 31
|
OR
|
95% CI
|
p value
|
OR
|
95% CI
|
p value
|
|
|
Age, (> 67 years), n (%)
|
7 (50.0%)
|
16 (51.6%)
|
0.9
|
0.3–3.3
|
0.92
|
|||
|
Sex, male, n (%)
|
8 (57.1%)
|
21 (67.7%)
|
0.6
|
0.2–2.3
|
0.49
|
|||
|
Etiology of MBO, n (%)
|
||||||||
|
Malignant biliary disease
|
4 (28.6%)
|
12 (38.7%)
|
0.6
|
0.1–2.4
|
0.51
|
|||
|
Malignant pancreatic disease
|
3 (21.4%)
|
10 (32.3%)
|
0.6
|
0.1–2.3
|
0.45
|
|||
|
Gastric cancer
|
6 (42.9%)
|
6 (19.4%)
|
3.1
|
0.8–12.9
|
0.11
|
|||
|
Colon cancer
|
0 (0%)
|
3 (9.7%)
|
0
|
0.13
|
||||
|
Hepatocellular carcinoma
|
1 (7.1%)
|
0 (0%)
|
–
|
0.13
|
||||
|
Type of MBO, n (%)
|
0.9
|
0.2–7.0
|
0.90
|
|||||
|
Primary disease
|
2 (14.3%)
|
4 (12.9%)
|
||||||
|
Recurrent disease
|
12 (85.7%)
|
27 (87.1%)
|
||||||
|
Liver metastasis
|
2 (14.3%)
|
10 (32.3%)
|
||||||
|
Lymph node metastasis
|
3 (21.4%)
|
4 (12.9%)
|
||||||
|
Local recurrence
|
7 (50.0%)
|
13 (41.9%)
|
||||||
|
Location of MBO, n (%)
|
2.2
|
0.6–8.3
|
0.26
|
|||||
|
Hilar or HJ anastomosis
|
8 (57.1%)
|
23 (74.2%)
|
||||||
|
Distal
|
6 (42.9%)
|
8 (25.8%)
|
||||||
|
Presence of peritoneal dissemination, n (%)
|
8 (57.1%)
|
5 (16.1%)
|
6.9
|
1.7–31.3
|
0.006
|
6.8
|
1.6–32.8
|
0.008
|
|
Digestive reconstruction, n (%)
|
||||||||
|
Modified child’s method
|
3 (21.4%)
|
15 (48.4%)
|
0.3
|
0.1–1.1
|
0.08
|
0.3
|
0.1–1.3
|
0.12
|
|
RY gastorejejunostomy
|
5 (35.7%)
|
8 (25.8%)
|
1.6
|
0.4–6.2
|
0.50
|
|||
|
RY hepaticojejunostomy
|
4 (28.6%)
|
5 (16.1%)
|
2.1
|
0.4–9.5
|
0.34
|
|||
|
Billroth II with gastrectomy
|
2 (14.3%)
|
3 (9.7%)
|
1.6
|
0.2–10.6
|
0.66
|
|||
|
Presence of native papilla, n (%)
|
7 (50.0%)
|
11 (35.5%)
|
1.8
|
0.5–6.7
|
0.36
|
|||
|
Time from surgery to ERCP (> 505 days), n (%)
|
5 (35.7%)
|
18 (58.1%)
|
0.4
|
0.1–1.4
|
0.16
|
|||
|
T-Bil (> 2.5 mg/dL), n (%)
|
9 (64.3%)
|
13 (41.9%)
|
2.5
|
0.7–9.8
|
0.16
|
|||
|
AST (> 80 IU/L), n (%)
|
8 (57.1%)
|
14 (45.2%)
|
1.6
|
0.5–6.0
|
0.46
|
|||
|
ALT (> 72 IU/L), n (%)
|
8 (57.1%)
|
14 (45.2%)
|
1.6
|
0.5–6.0
|
0.46
|
|||
|
γGTP (> 364 IU/L), n (%)
|
8 (57.1%)
|
13 (41.9%)
|
1.8
|
0.5–6.9
|
0.34
|
|||
|
ALP (> 1205 IU/L), n (%)
|
6 (42.9%)
|
15 (48.4%)
|
0.8
|
0.2–2.8
|
0.73
|
|||
|
Type of scope, n (%)
|
1.5
|
0.4–7.8
|
0.59
|
|||||
|
EI-580BT
|
3 (21.4%)
|
9 (29.0%)
|
||||||
|
Other scope
|
11 (78.6%)
|
22 (71.0%)
|
||||||